FDA Proposes to End Large-Scale GLP-1 Compounding
The FDA proposed April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need. Comment period open through June 29.
May 26, 2026 · 3 min read
The FDA announced on April 30, 2026, that it proposes not to include semaglutide, tirzepatide, or liraglutide on the 503B bulk drug substances list — a regulatory determination that, if finalized, would eliminate the legal basis for large-scale outsourcing facilities to manufacture compounded versions of these GLP-1 drugs from bulk. The public comment period remains open through June 29, 2026.
What happened
503B outsourcing facilities are large compounding operations that produce drugs in bulk and sell to hospitals, clinics, and pharmacies without patient-specific prescriptions. They operate under different rules from 503A compounding pharmacies, which mix medications for individual patients under specific prescriptions.
Federal law allows 503B facilities to compound copies of FDA-approved drugs from bulk substances when one of two conditions is met: the drug is on the FDA shortage list, or it's on the 503B bulks list because there's a demonstrated clinical need. Semaglutide was removed from the shortage list in February 2025; tirzepatide was removed in December 2024. That closed the shortage pathway for both drugs.
The FDA's April 30 proposal finds no clinical need for either drug to appear on the 503B bulks list — meaning the agency concludes that FDA-approved commercial versions adequately serve patients and that there is no documented unmet need requiring bulk-compounded alternatives. FDA Commissioner Marty Makary stated: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."
Liraglutide injection (the active ingredient in Saxenda and Victoza) remains on the FDA shortage list despite being included in the same proposal, meaning 503Bs can still legally compound it under the shortage pathway for now.
Why it matters
For patients who have relied on telehealth-prescripted compounded tirzepatide or semaglutide — at prices sometimes a third of the brand-name drugs — this is a significant development. If finalized, it would require 503B facilities to stop compounding these drugs from bulk, which is how most "compounded GLP-1" programs operate.
Important distinction: 503A pharmacies are not affected. The proposal covers 503B outsourcing facilities specifically. Traditional 503A compounding pharmacies — which compound from FDA-approved drug products (not bulk substances) for individual patients under specific prescriptions — continue to operate under different rules. Patient-specific compounding of semaglutide and tirzepatide remains legally available through 503A pharmacies with a valid prescription.
In practice, most large-scale telehealth compounding programs use 503B facilities. The cost advantage of compounded GLP-1s has rested on 503B manufacturing economics; 503A-based alternatives tend to be more expensive and less scalable. See compounded semaglutide safety for background on how these programs differ in quality oversight.
What to watch
This is a proposal, not a final rule. The comment period runs through June 29, 2026, and the FDA is required to review and respond to submitted comments before issuing a final determination. The Federal Register docket had received more than 370 comments as of this writing.
Compounders, telehealth platforms, and patient advocacy groups are expected to argue that access and cost barriers are themselves a clinical need — an argument the FDA explicitly considered and rejected in preliminary analysis. Whether the final rule will include carve-outs for specialty formulations (e.g., different dosing schedules, preservative-free versions) is unclear.
The adjacent question is litigation. Compounding industry groups challenged the FDA's earlier enforcement actions against semaglutide compounders in federal court; similar legal action targeting this 503B proposal is considered likely. Any final rule may be delayed or modified by judicial proceedings.
If you're currently using a compounded GLP-1 through a telehealth program, the practical advice is: nothing changes before June 29, and changes after that depend on the FDA's final rule and any court challenges. Read the compounded retatrutide legal status guide for broader context on compounding law and GLP-1s.
Sources
Sources